Intuitive Surgical Inc (ISRG) Stock Price & Analysis
Intuitive Surgical Inc (ISRG) rose 1.91% to USD 426.61 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
ISRG last closed at USD 418.61; the session ranged USD 417.55–430.85 on volume of 2,169,940 shares. Market capitalization is $151.09B, with a 52-week range of USD 396.68–603.88 (NMS). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 426.61 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 418.61 |
| Open | USD 421.03 |
| Day Range | USD 417.55 – 430.85 |
| 52-Week Range | USD 396.68 – 603.88 |
| Volume | 2,169,940 shares |
| Market Cap | $151.09B |
| Exchange | NMS |
Technical Analysis (ISRG)
Nexqual's technical model rates ISRG "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.92 (neutral) |
| vs SMA50 | Below (USD 446.12) |
| MACD | -8.88 (negative) |
Analyst Ratings (ISRG)
Wall Street analysts rate ISRG "Buy" based on 29 analysts, with a mean price target of USD 565.25 (range USD 366–750), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 565.25 |
| High Target | USD 750 |
| Low Target | USD 366 |
| Buy / Hold / Sell | 22 / 9 / 2 |
Earnings (ISRG)
| Next Earnings Date | 2026-07-21 |
|---|---|
| EPS Estimate | USD 2.5 |
| Revenue Estimate | $2.82B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.5 vs est 2.11 ▲ beat |
| 2025-12-31 | USD 2.53 vs est 2.27 ▲ beat |
| 2025-09-30 | USD 2.4 vs est 1.99 ▲ beat |
| 2025-06-30 | USD 2.19 vs est 1.92 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (ISRG)
| Total Revenue | $10.58B |
|---|---|
| Revenue Growth (YoY) | +23.00% |
| Gross Margin | +66.29% |
| Operating Margin | +30.87% |
| Profit Margin | +28.15% |
| ROE | +17.23% |
| Current Ratio | 4.61 |
| Total Cash | $4.52B |
| Total Debt | $0 |
| Free Cash Flow | $2.25B |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (ISRG)
Nexqual rates Intuitive Surgical Inc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 31% |
| Balance Sheet | Mixed — $4.52B cash, no debt |
| Cash Flow | Strong — FCF $2.25B, 22% margin |
| Efficiency | Solid — ROE 17%, ROA 10.2% |
Ownership (ISRG)
| Insider Ownership | +0.55% |
|---|---|
| Institutional Ownership | +89.25% |
| Shares Outstanding | 354.16M |
| Float | 352.10M |
| Short % of Float | +1.90% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (ISRG)
Intuitive Surgical Inc is led by David J. Rosa (age 57), CEO & Director, per Nexqual as of June 9, 2026 at 22:34 UTC.
| CEO & Director | David J. Rosa (age 57) |
|---|---|
| Executive VP, CFO & Enterprise Technology Leader | Jamie E. Samath (age 54) |
| Executive Vice President of Research, Corporate Development, Corporate Strategy & Intuitive Ventures | Christopher R. Carlson |
Major Backers & Investors (ISRG)
Notable institutional backers of Intuitive Surgical Inc include Price (T.Rowe) Associates Inc, Capital Group, Invesco, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 3.54% |
| Capital Group | 2.27% |
| Invesco | 2.15% |
| Morgan Stanley | 1.71% |
| FMR, LLC | 1.55% |
| JPMorgan | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.37% |
| BlackRock | 9.79% |
| State Street | 5.67% |
| Geode Capital | 2.39% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Intuitive Surgical Inc's Latest SEC 10-K Filing (filed 2026-02-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
- It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
- It sells its products through direct sales organizations, such as capital and clinical sales teams.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorpor | USD 445.77 | ▼ 0.24% |
| ILMN | Illumina, Inc. | USD 160.03 | ▼ 1.41% |
| NOW | ServiceNow, Inc. | USD 106.97 | ▼ 4.87% |
| CRM | Salesforce, Inc. | USD 175.35 | ▼ 5.55% |
| LRCX | Lam Research Corporation | USD 327.16 | ▲ 7.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.